Conference Correspondent

HER2+ Breast Cancer and CDK4/6 Inhibitors

Conference Correspondent 

Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: